EnVivo Pharmaceuticals, Progress on Major Drug Program Focusing on Alzheimer’s Diseases

October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, announced progress on several key programs for addressing Alzheimer’s*, Schizophrenia and Huntington’s diseases... The company believes that this lead compound represents one of the first highly potent, orally bio-available and brain-permeable HDAC inhibitors for neuro-degenerative diseases. HDAC inhibitors hold promise for treating the cognitive deficits of several diseases including Alzheimer’s disease... EnVivo's Press Release-